What is AZTR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AZTR?

P/E (TTM) is n/a and 52-week range is $0.10 to $1.09 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AZTR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AZTR?

The company profile lists revenue (TTM) near $408K, net income (TTM) near $-703M, EPS (TTM) near $-2.06 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Azitra Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Branford, Connecticut, US, 16.2M shares outstanding, ISIN US05479L3024 when available from company profile and filing metadata.

Azitra Inc

$AZTR

Health Care · Biotechnology

Run Scenarios

$0.13

-1.59%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The company is headquartered in Branford, Connecticut and currently employs 13 full-time employees. The company went IPO on 2023-06-16. The firm is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live bio therapeutic products. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, chronic, xerotic (abnormally dry), and scaly skin disease.

Employees

Website

azitrainc.com/

IPO

2023-06-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)